IOVA vs UTHR
Iovance Biotherapeutics, Inc. vs United Therapeutics — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
UTHR
United Therapeutics
72
Buy
| Metric | IOVA | UTHR |
|---|
| AI Score |
67
|
72
|
| Price |
$6.49
|
$514.89
|
| P/E Ratio |
-9.27×
|
17.05×
|
| ROE |
-56.0%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
86.1%
|
| Debt / Equity |
0.06×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
79.2
|
52.2
|
| Beta |
0.701
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus UTHR.
UTHR leads by 5 points.
UTHR scores 72/100 (Buy) versus IOVA at 67/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.